Insider trade

Officer received an award of 6,326 BIO derivative securities

Traded Sep 4, 2026 · Filed Sep 9, 2026

Bio-Rad LaboratoriesBIO

6,326
Derivative units

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Sep 4, 2026
Reporting period: Not applicable
Filed with the SEC: Sep 9, 2026

OfficerGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001453524-26-000002
Filed / recorded

Sep 9, 2026, 10:45 PM UTC

Added to OQRO

Oct 6, 2026, 4:40 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

BIO-RAD LABORATORIES, INC.

Issuer CIK

12208

Ticker

BIO BIO.B

Reporting person

Jonathan P. Divincenzo

Relationship

Officer

Officer title

President & COO

Security

Restricted Stock Units

Table

Derivative (Table II)

Transaction date

Sep 4, 2026

Transaction code

A

Shares / units

6,326

Price per share

$0.00

Acquired / disposed

Acquired (A)

Shares owned after

6,326

Ownership form

Direct

Amendment

No

Footnotes from the filing

Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
The restricted stock units vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining units vesting in equal quarterly installments thereafter.